Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 16, 2021 08:15 ET | Source: Vaccinex, Inc.

Vaccinex Reports Second Quarter 2021 Financial Results and Provides Corporate Update

Patients are currently being screened and enrolled in two studies of pepinemab as monotherapy in Alzheimer’s disease and in combination with KEYTRUDA® in Metastatic Head and Neck Squamous Cell...
June 30, 2021 08:00 ET | Source: Vaccinex, Inc.

Vaccinex to Chair Panel Q&A Session and Present Poster at the XV European Meeting on Glial Cells in Health and Disease

ROCHESTER, N.Y., June 30, 2021 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology Company pioneering a differentiated approach to treating neurodegenerative disease...
June 08, 2021 07:00 ET | Source: Vaccinex, Inc.

Vaccinex Announces Activation of Clinical Sites to Enroll Patients in Studies of Pepinemab as Single Agent in Alzheimer’s Disease and in Combination with KEYTRUDA® in Advanced, Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)

ROCHESTER, N.Y., June 08, 2021 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology Company pioneering a differentiated approach to treating neurodegenerative disease...
May 19, 2021 08:00 ET | Source: Vaccinex, Inc.

Vaccinex to Present at the Jefferies 2021 Virtual Healthcare Conference

ROCHESTER, N.Y., May 19, 2021 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and neurodegenerative...
May 17, 2021 08:15 ET | Source: Vaccinex, Inc.

Vaccinex Reports First Quarter 2021 Financial Results and Provides Corporate Update

Initiated Phase 2 study of pepinemab in combination with KEYTRUDA® in advanced, recurrent or metastatic head and neck cancer Announced publication of results from CLASSICAL-Lung phase 1b/2 clinical...
April 21, 2021 08:00 ET | Source: Vaccinex, Inc.

Vaccinex Announces Publication of Results from CLASSICAL-Lung Phase 1b/2 Clinical Trial in Non-Small Cell Lung Cancer in the Peer-Reviewed Journal Clinical Cancer Research

ROCHESTER, N.Y., April 21, 2021 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and...
March 16, 2021 08:05 ET | Source: Vaccinex, Inc.

Vaccinex Reports Fourth Quarter 2020 Financial Results and Provides Corporate Update

Reported top-line results from Phase 2 SIGNAL study that indicates potential cognitive benefit of pepinemab in neurodegenerative disease. New Alzheimer’s study expected to begin enrollment in Q2 ...
March 11, 2021 08:00 ET | Source: Vaccinex, Inc.

Vaccinex to Present at the Oppenheimer 31st Annual Healthcare Conference

ROCHESTER, N.Y., March 11, 2021 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and...
February 22, 2021 08:30 ET | Source: Vaccinex, Inc.

Vaccinex Announces Licensing of Anti-CCR8 Antibody to Surface Oncology

ROCHESTER, N.Y., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and neurodegenerative...
February 19, 2021 08:00 ET | Source: Vaccinex, Inc.

Vaccinex Announces Signing of Two Multi-Project Deals with Leading Pharmaceutical Companies Focused on Leveraging Its ActivMAb® Platform

ROCHESTER, N.Y., Feb. 19, 2021 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and neurodegenerative...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right